Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Lipodystrophy Clear all
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Jul 23, 2026, 11:25 AM EDT
Completed No phase listed Observational

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

NCT00225082
View directory record Official record
Conditions
HIV Infection
Interventions
Nucleoside analogue switch
Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Endothelial Dysfunction as a Risk Factor in HIV Study

NCT00039663
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin, Gemfibrozil, Rosiglitazone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Rosiglitazone Effect on Mitochondria and Lipoatrophy

NCT00367744
View directory record Official record
Conditions
HIV Infections
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

TH9507 in Patients With HIV-Associated Lipodystrophy

NCT00123253
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
TH9507
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 4 Interventional

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

NCT00005764
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Not applicable Interventional Results available

Effects of Growth Hormone Releasing Hormone in HIV

NCT01263717
View directory record Official record
Conditions
HIV, HIV Lipodystrophy
Interventions
tesamorelin, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome

NCT00362440
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
Leptin, Pioglitazone or metformin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 23, 2026, 11:25 AM EDT
Completed No phase listed Observational

The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children

NCT00006064
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome, Lipodystrophy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Study of Lifestyle Modification in HIV Lipodystrophy

NCT00111358
View directory record Official record
Conditions
HIV, Metabolic Diseases
Interventions
Lifestyle Modification, No lifestyle modification
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2011 · Synced Jul 23, 2026, 11:25 AM EDT
Terminated Phase 4 Interventional Results available

Body Composition and Adipose Tissue in HIV

NCT03226821
View directory record Official record
Conditions
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
Interventions
Tesamorelin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 68 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 23, 2026, 11:25 AM EDT
Completed No phase listed Observational

Growth Hormone Dynamics and Cardiac Steatosis in HIV

NCT03826160
View directory record Official record
Conditions
Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
23 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Jul 23, 2026, 11:25 AM EDT
Terminated Phase 1 Interventional

Effects of IGF-I in HIV Metabolic Disease

NCT01329744
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
mecasermin, Placebo control
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

NCT00246402
View directory record Official record
Conditions
Insulin Resistance, Cardiovascular Diseases, Heart Diseases, HIV Infections, Hypertriglyceridemia, Hyperlipidemia
Interventions
Acipimox
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jul 23, 2026, 11:25 AM EDT
Withdrawn No phase listed Observational

Egrifta Replacement and Sleep Disordered Breathing

NCT01788462
View directory record Official record
Conditions
Lipodystrophy
Interventions
Tesamorelin (Egrifta)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

NCT00021463
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2011 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340
View directory record Official record
Conditions
HIV-associated Lipodystrophy Syndrome
Interventions
GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

NCT00082628
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Placebo, Serostim® 4 mg, Serostim® 2 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 23, 2026, 11:25 AM EDT
Completed No phase listed Observational

Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

NCT00360932
View directory record Official record
Conditions
Facial Lipoatrophy
Interventions
SCULPTRA (poly-L-lactic acid injection)
Device
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Approaches to HAART-Induced Lipodystrophy

NCT00461552
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Leptin, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
14 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Not applicable Interventional Results available

HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)

NCT01023620
View directory record Official record
Conditions
HIV Infections
Interventions
Pioglitazone, Observation
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 4 Interventional

A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy

NCT00006190
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Nelfinavir mesylate, Stavudine, Lamivudine, Efavirenz
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jul 23, 2026, 11:25 AM EDT
Completed No phase listed Observational

Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs

NCT00006290
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2008 · Synced Jul 23, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Metabolic Abnormalities in HIV-infected Persons

NCT01612858
View directory record Official record
Conditions
Lipodystrophy, HIV Infection
Interventions
Metformin, Pioglitazone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2016 · Synced Jul 23, 2026, 11:25 AM EDT